|McLean, Va. (May 14, 2014) – Food Allergy Research & Education (FARE), the nation’s leading nonprofit dedicated to food allergy, announced Wednesday that physician and human geneticist David Altshuler, M.D., Ph.D., has been elected to its Board of Directors, and leading food allergy investigator Stacie M. Jones, M.D., has been elected to its Research Advisory Board.
“As we continue to seek a cure for food allergies and to provide evidence-based information that helps people live well with food allergies, it is critical that FARE continues to benefit from the insights of leading scientists and medical experts,” said Todd J. Slotkin, chairman of FARE’s Board of Directors. “We are pleased to welcome David to our Board of Directors and Stacie to our Research Advisory Board. Their wealth of expertise will help us better serve our mission and the needs of the food allergy community.”
Altshuler, a founding member, deputy director and chief academic officer of the Broad Institute of MIT and Harvard, brings his medical and scientific expertise to FARE’s board of directors. Altshuler, the father of two children with multiple food allergies, is a professor of genetics and medicine at Harvard Medical School and at Massachusetts General Hospital, and adjunct professor of biology at the Massachusetts Institute of Technology. He is a member of the Board of Directors of Vertex Pharmaceuticals, and was honored by the White House in 2013 as a “Champion of Change” for his vision and commitment to open science, and his work contributed to the identification of gene variants that are associated with the risk of common conditions, including type 2 diabetes. Altshuler also participated in FARE’s 2013 Research Retreat, which formed the basis for “A Vision and Plan for Food Allergy Research,” FARE’s strategic plan for research.
“FARE is doing tremendously important work on behalf of the 15 million Americans with food allergies,” Altshuler said. “As a physician-scientist and as the parent of children with food allergies, this is an exciting time to be joining the Board. I am proud to be involved in FARE’s continued search for viable treatments and work to keep individuals with food allergies safe and included.”
>FARE’s 20-member board of directors includes professionals with a wide array of expertise who guide FARE in its mission and work. Nearly every member of the board is the parent or grandparent of a child with food allergy.
Jones, a professor and chief of allergy and immunology in the Department of Pediatrics at the University of Arkansas for Medical Sciences and Arkansas Children’s Hospital, has directed and participated in numerous clinical trials on emerging therapies for food allergy. Jones and her team are also part of the five-center, NIH-funded Consortium of Food Allergy Research, which was developed to improve understanding of mechanisms of food allergy and to develop new treatments for children and adults with food allergies, and she serves as the Study Co-Chair for the NIH-funded, Immune Tolerance Network “IMPACT” Trial. Jones has served on national scientific review panels and as an expert for the NIH Guidelines for the Diagnosis and Management of Food Allergy. She has served as a member of FARE’s Medical Advisory Board and currently sits on the organization’s Education Working Group, and she also participated in FARE’s 2013 Research Retreat. She now joins FARE’s seven-member Research Advisory Board, which plays an integral role in carrying out FARE’s strategic plan for research.
“As a scientist who shares the desire to find therapies that will reduce the risk of life-threatening reactions and improve the lives of families managing food allergies, it is an honor to continue working with FARE in a new role as a member of the Research Advisory Board,” Jones said. “I am pleased to join this esteemed group as it works to help turn FARE’s strategic plan for research into a reality.”
Learn more about FARE and food allergies at www.foodallergy.org.